Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

HTTPS

Secure .gov websites use HTTPS
A lock (LockA locked padlock) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

HHS.gov
  • About HHS
  • Programs & Services
  • Grants & Contracts
  • Laws & Regulations

Breadcrumb

  1. Home
  2. About
  3. News
  4. Biden-Harris Administration secures 105 million doses of Pfizer’s latest COVID-19 vaccine for fall vaccination campaign
  • News
  • Blog
  • HHS Live
  • Podcasts
  • Media Guidelines for HHS Employees
FOR IMMEDIATE RELEASE
June 29, 2022
Contact: HHS Press Office
202-690-6343
media@hhs.gov

Biden-Harris Administration secures 105 million doses of Pfizer’s latest COVID-19 vaccine for fall vaccination campaign

The U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense, today announced an agreement to purchase 105 million doses of Pfizer’s COVID-19 vaccine for a fall vaccination campaign, with options for up to 300 million doses. The contract announcement follows a June 28 meeting of the U.S. Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee meeting, which recommended the inclusion of an Omicron component for COVID-19 booster vaccines in the U.S.

“Vaccines have been a game-changer in our fight against COVID-19, allowing people to return to normal activities knowing that vaccines protect from severe illness,” said HHS Secretary Xavier Becerra. “The Biden-Harris Administration is committed to doing everything we can to continue to make vaccines free and widely available to Americans – and this is an important first step to preparing us for the fall.”

The $3.2 billion contract includes a combination of adult and pediatric doses with a portion of the adult doses provided as single-dose vials, a first for COVID-19 vaccines. Pending FDA authorization of the vaccine and a recommendation by the Centers for Disease Control and Prevention, HHS could expect to receive the first deliveries of the vaccine in early fall.

“Over the past 18 months, we have procured and delivered more than 750 million doses of COVID-19 vaccine nationwide, contributing to two-thirds of American adults being fully vaccinated,” said HHS Assistant Secretary for Preparedness and Response (ASPR) Dawn O’Connell. “We look forward to taking delivery of these new variant-specific vaccines and working with state and local health departments, pharmacies, health care providers, federally qualified health centers, and other partners to make them available in communities around the country this fall.”

Earlier this month, in the absence of additional COVID-19 funding from Congress, the Administration was forced to reallocate $10 billion in existing funding, pulling billions of dollars from COVID-19 response efforts in order to pay for additional vaccines and treatments. The funding for this new Pfizer contract is being paid for with a portion of that reallocated funding. To award the contract, the Biomedical Advanced Research and Development Authority (BARDA), part of ASPR, collaborated with the DOD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and Army Contracting Command.

About HHS, ASPR, and BARDA
HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. ASPR leads HHS in preparing the nation to respond to and recover from adverse health effects of emergencies, supporting communities’ ability to withstand adversity, strengthening health and response systems, and enhancing national health security. Within ASPR, BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products needed to combat health security threats.

About the JPEO-CBRND
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) protects the Joint Force by providing medical countermeasures and defense equipment against chemical, biological, radiological and nuclear (CBRN) threats. JPEO-CBRND’s goal is to enable the Joint Force to fight and win unencumbered by a CBRN environment. JPEO-CBRND facilitates the rapid response, advanced development, manufacturing and acquisition of medical solutions, such as vaccines, therapeutics, and diagnostics, to combat CBRN and emerging threats such as COVID-19. To learn more about JPEO-CBRND’s COVID-19 response, visit https://www.jpeocbrnd.osd.mil/coronavirus or follow JPEO-CBRND on social media at @JPEOCBRND.

###
Note: All HHS press releases, fact sheets and other news materials are available at https://www.hhs.gov/news.
Like HHS on Facebook, follow HHS on Twitter @HHSgov, and sign up for HHS Email Updates.
Last revised: June 29, 2022

Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases

Sign Up

Subscribe to RSS

Receive latest updates

Subscribe to our RSS

Related News Releases

  • Biden-Harris Administration Awards $600 Million to Bolster US Manufacturing of COVID-19 Tests and Announces the Re-Opening of COVIDTests.gov

  • HHS Awards $45 Million in Grants to Expand Access to Care for People with Long COVID

  • Statement from HHS Secretary Xavier Becerra Following CDC’s Recommendation of Updated COVID-19 Vaccines

Related Blog Posts

  • HHS Blog thumbnail

    Driving Long COVID Innovation with Health+ Human-Centered Design

  • Assistant Secretary for Global Affairs Loyce Pace

    U.S. Summary of the 75th World Health Assembly

  • HHS Blog thumbnail

    Working Day or Night, NDMS Teams Deploy to Support Healthcare Facilities and Save Lives in Communities Overwhelmed by COVID-19: “We are NDMS…That’s What We do”

Media Inquiries

For general media inquiries, please contact media@hhs.gov.

Content created by Assistant Secretary for Public Affairs (ASPA)
Content last reviewed June 29, 2022
Back to top
  • Contact HHS
  • Careers
  • HHS FAQs
  • Nondiscrimination Notice
  • HHS Archive
  • Accessibility
  • Privacy Policy
  • Viewers & Players
  • Budget/Performance
  • Inspector General
  • Web Site Disclaimers
  • EEO/No Fear Act
  • FOIA
  • The White House
  • USA.gov
  • Vulnerability Disclosure Policy

Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases.

Sign Up
HHS Logo

HHS Headquarters

200 Independence Avenue, S.W.
Washington, D.C. 20201
Toll Free Call Center: 1-877-696-6775​